Urinary Pseudouridine Excretion in Myelomatosis
Author Information
Author(s): S.H. Sørensen, D.A. Brown, E.H. Cooper, K.A. Kelly, I.C.M. MacLennan
Primary Institution: Unit for Cancer Research, School of Medicine, Leeds; West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham; Department of Immunology, The Medical School, Birmingham
Hypothesis
Does urinary pseudouridine excretion serve as a prognostic indicator in myelomatosis?
Conclusion
Urinary pseudouridine levels are significantly higher in myelomatosis patients compared to controls, but add little prognostic information when serum beta-2-microglobulin levels are considered.
Supporting Evidence
- Urinary pseudouridine levels at presentation are significantly related to prognosis, with higher levels indicating poorer prognosis.
- The mean urinary pseudouridine level in myeloma patients was 40.7 nmol/umol ucr compared to 25.5 nmol/umol ucr in controls.
- Urinary pseudouridine excretion was found to be independent of serum paraprotein, serum creatinine, and urinary light chain production.
Takeaway
This study found that people with myelomatosis have more pseudouridine in their urine than healthy people, but it doesn't help much in predicting how sick they will get if we already know their serum levels.
Methodology
Patients were part of the Medical Research Council Vth myelomatosis trial, and urinary pseudouridine was isolated and assayed using high-performance liquid chromatography.
Limitations
The study primarily involved patients under 75 years old, which may limit the applicability of the findings to older populations.
Participant Demographics
264 patients aged less than 75 years and 31 healthy controls aged between 20 and 60 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website